申请人:Medivation Technologies, Inc.
公开号:US20130184303A1
公开(公告)日:2013-07-18
This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
本公开涉及新的杂环化合物,可用于调节个体的组胺受体。描述了吡啶并[4,3-b]吲哚,以及包含该化合物的制药组合物和使用该化合物进行各种治疗应用的方法,包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。